The company plans to deploy these funds to further develop a suite of the oral microbiome and human gene expression tests as well as launch its brand of precision biotics
Genefitletics, a direct-to-consumer microbiome company, pioneering the application of microbial technologies to save human health, has raised an undisclosed amount at a pre-money valuation of Rs 7.5 crore from a group of Angels. The company is working on discoveries in microbial science, to bridge the gap between scientific advancements and human health, the firm said.
The company plans to deploy these funds to further develop a suite of oral microbiome and human gene expression tests as well as launch its brand of precision biotics. The funds will also be used to further develop machine learning models for human biology, to decode the root cause of poor health.
Sushant Kumar, Founder & CEO, Genefitletics, said, “Modern healthcare model is rewarded for management of symptoms of chronic diseases, not prevention or cure. Consider this if one acquires an autoimmune condition at a young age, he becomes a lifetime subscriber of a pharmaceutical company. The healthcare system focuses on suppressing the immune system rather than finding the root cause of the disease. As a result, people develop more diseases and side effects and are prescribed more drugs. What happens next is a vicious cycle. This disaster started in the early 1800s with the introduction of germ theory.”
